II
NKTR icon

Inspire Investing’s Nektar Therapeutics NKTR Stock Holding History

Inspire Investing’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48 Buy
+1
New +$57 ﹤0.01% 1075
2025
Q4 		– Hold
0
– – – 1104
2023
Q3 		– Sell
-36,770
Closed -$317K – 858
2023
Q2 		$317K Buy
36,770
+10,520
+40% +$112K 0.04% 432
2023
Q1 		$277K Buy
26,250
+19,217
+273% +$581K 0.04% 422
2022
Q4 		$238K Buy
7,033
+2,715
+63% +$131K 0.03% 369
2022
Q3 		$207K Buy
4,318
+592
+16% +$35.2K 0.03% 520
2022
Q2 		$212K Buy
3,726
+797
+27% +$50.3K 0.03% 558
2022
Q1 		$237K Buy
2,929
+1,731
+144% +$256K 0.03% 430
2021
Q4 		$243K Buy
1,198
+353
+42% +$76.6K 0.03% 765
2021
Q3 		$228K Buy
+845
New +$203K 0.03% 636
2020
Q2 		– Sell
-1
Closed – – 636
2020
Q1 		$0 Buy
+1
New +$309 ﹤0.01% 771
2018
Q1 		– Sell
-197
Closed -$177K – 522
2017
Q4 		$177K Buy
+197
New +$117K 0.15% 146

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Inspire Investing's NKTR Position: Q1 2026 in Review

Inspire Investing opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 1 share worth $48. The stake represents ﹤0.01% of the portfolio and ranks #1075 among its holdings. This is a return to the name: Inspire Investing previously reported a position in NKTR as recently as Q2 2023.

Inspire Investing first reported a position in NKTR in Q4 2017 and has held it in 11 quarters since. The position peaked at $317K in Q2 2023. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Inspire Investing held 1 share of Nektar Therapeutics worth $48 as of Q1 2026.
  • Nektar Therapeutics was a new Inspire Investing position in Q1 2026.
  • Nektar Therapeutics made up ﹤0.01% of Inspire Investing's portfolio in Q1 2026, its #1075 holding.
  • Inspire Investing first reported a position in Nektar Therapeutics in Q4 2017 and has held it in 11 quarters since.
  • Inspire Investing's Nektar Therapeutics position peaked at $317K in Q2 2023.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Inspire Investing's 13F filing for Q1 2026, filed 23 Apr 2026.